#BEGIN_DRUGCARD DB02767

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
Not Available

# ChEBI_ID:
Not Available

# Chemical_Formula:
C14H28O3

# Chemical_IUPAC_Name:
(3R)-3-hydroxytetradecanoic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Not Available

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
3-Hydroxy-Myristic Acid

# HET_ID:
FTT

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C14H28O3/c1-2-3-4-5-6-7-8-9-10-11-13(15)12-14(16)17/h13,15H,2-12H2,1H3,(H,16,17)/t13-/m1/s1

# InChI_Key:
InChIKey=ATRNZOYKSNPPBF-CYBMUJFWSA-N

# Indication:
Not Available

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
2767

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
244.3703

# Molecular_Weight_Mono:
244.203844762

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1FI1

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
4.69

# Predicted_LogS:
-3.9

# Predicted_Water_Solubility:
2.99e-02 g/l

# Primary_Accession_No:
DB02767

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
5288266

# PubChem_Substance_ID:
46505492

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT01506

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
[H][C@@](O)(CCCCCCCCCCC)CC(O)=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:21:28 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Cell outer membrane
multi-pass membrane protein

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
M12486

# Drug_Target_1_GenBank_ID_Protein:
2226438

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
fhuA

# Drug_Target_1_Gene_Sequence:
>2244 bp
ATGGCGCGTTCCAAAACTGCTCAGCCAAAACACTCACTGCGTAAAATCGCAGTTGTAGTA
GCCACAGCGGTTAGCGGCATGTCTGTTTATGCACAGGCAGCGGTTGAACCGAAAGAAGAC
ACTATCACCGTTACCGCTGCACCTGCGCCGCAAGAAAGCGCATGGGGGCCTGCTGCAACT
ATTGCGGCGCGACAGTCTGCTACCGGCACTAAAACCGATACGCCGATTCAAAAAGTGCCA
CAGTCTATTTCTGTTGTGACCGCCGAAGAGATGGCGCTGCATCAGCCGAAGTCGGTAAAA
GAAGCGCTTAGCTACACGCCGGGTGTCTCTGTTGGTACGCGTGGCGCATCCAACACCTAT
GACCACCTGATCATTCGCGGCTTTGCGGCAGAAGGCCAAAGCCAGAATAACTATCTGAAT
GGCCTGAAGTTGCAGGGCAACTTCTATAACGATGCGGTCATTGACCCGTATATGCTGGAA
CGCGCTGAAATTATGCGTGGCCCGGTTTCCGTGCTTTACGGTAAAAGCAGTCCTGGCGGC
CTGTTGAATATGGTCAGCAAGCGTCCGACCACCGAACCGCTGAAAGAAGTTCAGTTTAAA
GCCGGTACTGACAGCCTGTTCCAGACTGGTTTTGACTTTAGCGATTCGTTGGATGATGAC
GGTGTTTACTCTTATCGCCTGACCGGTCTTGCGCGTTCTGCCAATGCCCAGCAGAAAGGG
TCAGAAGAGCAGCGTTATGCTATTGCACCGGCGTTCACCTGGCGTCCGGATGATAAAACC
AATTTTACCTTCCTTTCTTACTTCCAGAACGAGCCGGAAACCGGTTATTACGGCTGGTTG
CCGAAAGAGGGAACCGTTGAGCCGCTGCCGAACGGTAAGCGTCTGCCGACAGACTTTAAT
GAAGGGGCGAAGAACAACACCTATTCTCGTAATGAGAAGATGGTCGGCTACAGCTTCGAT
CACGAATTTAACGACACCTTTACTGTGCGTCAGAACCTGCGCTTTGCTGAAAACAAAACC
TCGCAAAACAGCGTTTATGGTTACGGCGTCTGCTCCGATCCGGCGAATGCTTACAGCAAA
CAGTGTGCGGCATTAGCGCCAGCGGATAAAGGCCATTATCTGGCACGTAAATACGTCGTT
GATGATGAGAAGCTGCAAAACTTCTCCGTTGATACCCAGTTGCAGAGCAAGTTTGCCACT
GGCGATATCGACCACACCCTGCTGACCGGTGTCGACTTTATGCGTATGCGTAATGACATC
AACGCCTGGTTTGGTTACGACGACTCTGTGCCACTGCTCAATCTGTACAATCCGGTGAAT
ACCGATTTCGACTTCAATGCCAAAGATCCGGCAAACTCCGGCCCTTACCGCATTCTGAAT
AAACAGAAACAAACGGGCGTTTATGTTCAGGATCAGGCGCAGTGGGATAAAGTGCTGGTC
ACCCTAGGCGGTCGTTATGACTGGGCAGATCAAGAATCTCTTAACCGCGTTGCCGGGACG
ACCGATAAACGTGATGACAAACAGTTTACCTGGCGTGGTGGTGTTAACTACCTGTTTGAT
AATGGTGTAACACCTTACTTCAGCTATAGCGAATCGTTTGAACCTTCTTCGCAAGTTGGG
AAGGATGGTAATATTTTCGCACCGTCTAAAGGTAAGCAGTATGAAGTCGGCGTGAAATAT
GTACCGGAAGATCGTCCGATTGTAGTTACTGGTGCCGTGTATAATCTCACTAAAACCAAC
AACCTGATGGCGGACCCTGAGGGTTCCTTCTTCTCGGTTGAAGGTGGCGAGATCCGCGCA
CGTGGCGTAGAAATCGAAGCGAAAGCGGCGCTGTCGGCGAGTGTTAACGTAGTCGGTTCT
TATACTTACACCGATGCGGAATACACCACCGATACTACCTATAAAGGCAATACGCCTGCA
CAGGTGCCAAAACACATGGCTTCGTTGTGGGCTGACTACACCTTCTTTGACGGTCCGCTT
TCAGGTCTGACGCTGGGCACCGGTGGTCGTTATACTGGCTCCAGTTATGGTGATCCGGCT
AACTCCTTTAAAGTGGGAAGTTATACGGTCGTGGATGCGTTAGTACGTTATGATCTGGCG
CGAGTCGGCATGGCTGGCTCCAACGTGGCGCTGCATGTTAACAACCTGTTCGATCGTGAA
TACGTCGCCAGCTGCTTTAACACTTATGGCTGCTTCTGGGGCGCAGAACGTCAGGTCGTT
GCAACCGCAACCTTCCGTTTCTAA

# Drug_Target_1_General_Function:
Inorganic ion transport and metabolism

# Drug_Target_1_General_References:
10850805	Ferguson AD, Braun V, Fiedler HP, Coulton JW, Diederichs K, Welte W: Crystal structure of the antibiotic albomycin in complex with the outer membrane transporter FhuA. Protein Sci. 2000 May;9(5):956-63.
2823072	Burkhardt R, Braun V: Nucleotide sequence of the fhuC and fhuD genes involved in iron (III) hydroxamate transport: domains in FhuC homologous to ATP-binding proteins. Mol Gen Genet. 1987 Aug;209(1):49-55.
3079747	Coulton JW, Mason P, Cameron DR, Carmel G, Jean R, Rode HN: Protein fusions of beta-galactosidase to the ferrichrome-iron receptor of Escherichia coli K-12. J Bacteriol. 1986 Jan;165(1):181-92.
7515827	Braun V, Killmann H, Benz R: Energy-coupled transport through the outer membrane of Escherichia coli small deletions in the gating loop convert the FhuA transport protein into a diffusion channel. FEBS Lett. 1994 Jun 6;346(1):59-64.
8202364	Fujita N, Mori H, Yura T, Ishihama A: Systematic sequencing of the Escherichia coli genome: analysis of the 2.4-4.1 min (110,917-193,643 bp) region. Nucleic Acids Res. 1994 May 11;22(9):1637-9.
8617231	Bonhivers M, Ghazi A, Boulanger P, Letellier L: FhuA, a transporter of the Escherichia coli outer membrane, is converted into a channel upon binding of bacteriophage T5. EMBO J. 1996 Apr 15;15(8):1850-6.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.
9856937	Ferguson AD, Hofmann E, Coulton JW, Diederichs K, Welte W: Siderophore-mediated iron transport: crystal structure of FhuA with bound lipopolysaccharide. Science. 1998 Dec 18;282(5397):2215-20.
9865695	Locher KP, Rees B, Koebnik R, Mitschler A, Moulinier L, Rosenbusch JP, Moras D: Transmembrane signaling across the ligand-gated FhuA receptor: crystal structures of free and ferrichrome-bound states reveal allosteric changes. Cell. 1998 Dec 11;95(6):771-8.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
2427

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
82183

# Drug_Target_1_Name:
Ferrichrome-iron receptor

# Drug_Target_1_Number_of_Residues:
747

# Drug_Target_1_PDB_ID:
1BY3

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00593	TonB_dep_Rec
PF07715	Plug

# Drug_Target_1_Protein_Sequence:
>Ferrichrome-iron receptor precursor
MARSKTAQPKHSLRKIAVVVATAVSGMSVYAQAAVEPKEDTITVTAAPAPQESAWGPAAT
IAARQSATGTKTDTPIQKVPQSISVVTAEEMALHQPKSVKEALSYTPGVSVGTRGASNTY
DHLIIRGFAAEGQSQNNYLNGLKLQGNFYNDAVIDPYMLERAEIMRGPVSVLYGKSSPGG
LLNMVSKRPTTEPLKEVQFKAGTDSLFQTGFDFSDSLDDDGVYSYRLTGLARSANAQQKG
SEEQRYAIAPAFTWRPDDKTNFTFLSYFQNEPETGYYGWLPKEGTVEPLPNGKRLPTDFN
EGAKNNTYSRNEKMVGYSFDHEFNDTFTVRQNLRFAENKTSQNSVYGYGVCSDPANAYSK
QCAALAPADKGHYLARKYVVDDEKLQNFSVDTQLQSKFATGDIDHTLLTGVDFMRMRNDI
NAWFGYDDSVPLLNLYNPVNTDFDFNAKDPANSGPYRILNKQKQTGVYVQDQAQWDKVLV
TLGGRYDWADQESLNRVAGTTDKRDDKQFTWRGGVNYLFDNGVTPYFSYSESFEPSSQVG
KDGNIFAPSKGKQYEVGVKYVPEDRPIVVTGAVYNLTKTNNLMADPEGSFFSVEGGEIRA
RGVEIEAKAALSASVNVVGSYTYTDAEYTTDTTYKGNTPAQVPKHMASLWADYTFFDGPL
SGLTLGTGGRYTGSSYGDPANSFKVGSYTVVDALVRYDLARVGMAGSNVALHVNNLFDRE
YVASCFNTYGCFWGAERQVVATATFRF

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
1-33

# Drug_Target_1_Specific_Function:
This receptor binds the ferrichrome-iron ligand. It interacts with the tonB protein, which is responsible for energy coupling of the ferrichrome-promoted iron transport system. Acts as a receptor for bacteriophage T5 as well as T1, phi80 and colicin M. Binding of T5 triggers the opening of a high conductance ion channel. Can also transport the antibiotic albomycin

# Drug_Target_1_SwissProt_ID:
P06971

# Drug_Target_1_SwissProt_Name:
FHUA_ECOLI

# Drug_Target_1_Synonyms:
Ferric hydroxamate receptor
Ferric hydroxamate uptake
Ferrichrome-iron receptor precursor

# Drug_Target_1_Theoretical_pI:
5.35

# Drug_Target_1_Transmembrane_Regions:
193-201
207-215
223-231
246-255
260-268
313-321
327-335
388-396
405-413
465-473
478-486
509-517
523-531
552-560
566-574
602-610
614-622
646-654
662-670
690-698
706-714
738-746

# Drug_Target_2_Cellular_Location:
Cell inner membrane

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_2_Essentiality:
Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
K00431

# Drug_Target_2_GenBank_ID_Protein:
148023

# Drug_Target_2_GeneCard_ID:
tonB

# Drug_Target_2_Gene_Name:
tonB

# Drug_Target_2_Gene_Sequence:
>735 bp
GAGACCTGGTTTTTCTACTGAAATGATTATGACTTCAATGACCCTTGATTTACCTCGCCG
CTTCCCCTGGCCGACGTTACTTTCGGTCTGCATTCATGGTGCTGTTGTGGCGGGTCTGCT
CTATACCTCGGTACATCAGGTTATTGAACTACCTGCGCCTGCGCAGCCGATTTCTGTCAC
GATGGTTACGCCTGCTGATCTCGAACCGCCACAAGCCGTTCAGCCGCCACCGGAGCCGGT
GGTAGAGCCAGAACCGGAACCTGAGCCGATCCCCGAACCGCCAAAAGAAGCACCGGTGGT
CATTGAAAAGCCGAAGCCGAAACCTAAGCCAAAACCGAAGCCGGTGAAAAAGGTACAGGA
GCAGCCAAAACGCGATGTCAAACCCGTAGAGTCGCGTCCGGCATCACCGTTTGAAAATAC
GGCACCGGCACGCCTGACATCAAGTACAGCAACGGCTGCAACCAGCAAGCCGGTTACCAG
TGTGGCTTCAGGACCACGCGCATTAAGCCGTAATCAGCCGCAGTATCCGGCACGAGCACA
GGCATTGCGCATTGAAGGGCAGGTTAAAGTTAAATTTGACGTTACGCCGGATGGTCGCGT
GGATAACGTACAAATCCTCTCAGCCAAGCCTGCGAACATGTTTGAGCGTGAGGTGAAAAA
TGCGATGCGCAGATGGCGTTATGAGCCGGGTAAGCCAGGCAGTGGGATTGTGGTGAATAT
CCTGTTTAAAATTAA

# Drug_Target_2_General_Function:
Cell wall/membrane/envelope biogenesis

# Drug_Target_2_General_References:
11328822	Chang C, Mooser A, Pluckthun A, Wlodawer A: Crystal structure of the dimeric C-terminal domain of TonB reveals a novel fold. J Biol Chem. 2001 Jul 20;276(29):27535-40. Epub 2001 Apr 27.
16738553	Hayashi K, Morooka N, Yamamoto Y, Fujita K, Isono K, Choi S, Ohtsubo E, Baba T, Wanner BL, Mori H, Horiuchi T: Highly accurate genome sequences of Escherichia coli K-12 strains MG1655 and W3110. Mol Syst Biol. 2006;2:2006.0007. Epub 2006 Feb 21.
1885532	Roof SK, Allard JD, Bertrand KP, Postle K: Analysis of Escherichia coli TonB membrane topology by use of PhoA fusions. J Bacteriol. 1991 Sep;173(17):5554-7.
6310567	Postle K, Good RF: DNA sequence of the Escherichia coli tonB gene. Proc Natl Acad Sci U S A. 1983 Sep;80(17):5235-9.
8316087	Karlsson M, Hannavy K, Higgins CF: A sequence-specific function for the N-terminal signal-like sequence of the TonB protein. Mol Microbiol. 1993 Apr;8(2):379-88.
9097039	Aiba H, Baba T, Hayashi K, Inada T, Isono K, Itoh T, Kasai H, Kashimoto K, Kimura S, Kitakawa M, Kitagawa M, Makino K, Miki T, Mizobuchi K, Mori H, Mori T, Motomura K, Nakade S, Nakamura Y, Nashimoto H, Nishio Y, Oshima T, Saito N, Sampei G, Horiuchi T, et al.: A 570-kb DNA sequence of the Escherichia coli K-12 genome corresponding to the 28.0-40.1 min region on the linkage map. DNA Res. 1996 Dec 31;3(6):363-77.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-62.

# Drug_Target_2_HGNC_ID:
Not Available

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
6524

# Drug_Target_2_Locus:
Not Available

# Drug_Target_2_Molecular_Weight:
26094.1

# Drug_Target_2_Name:
Protein tonB

# Drug_Target_2_Number_of_Residues:
239

# Drug_Target_2_PDB_ID:
1XX3

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF03544	TonB

# Drug_Target_2_Protein_Sequence:
>Protein tonB
MTLDLPRRFPWPTLLSVCIHGAVVAGLLYTSVHQVIELPAPAQPISVTMVTPADLEPPQA
VQPPPEPVVEPEPEPEPIPEPPKEAPVVIEKPKPKPKPKPKPVKKVQEQPKRDVKPVESR
PASPFENTAPARLTSSTATAATSKPVTSVASGPRALSRNQPQYPARAQALRIEGQVKVKF
DVTPDGRVDNVQILSAKPANMFEREVKNAMRRWRYEPGKPGSGIVVNILFKINGTTEIQ

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
Interacts with outer membrane receptor proteins that carry out high-affinity binding and energy dependent uptake into the periplasmic space of specific substrates such as cobalamin, and various iron compounds (such as iron dicitrate, enterochelin, aerobactin, etc.). In the absence of tonB these receptors bind their substrates but do not carry out active transport. TonB also interacts with some colicins and is involved in the energy- dependent, irreversible steps of bacteriophages phi 80 and T1 infection. It could act to transduce energy from the cytoplasmic membrane to specific energy-requiring processes in the outer membrane, resulting in the release into the periplasm of ligands bound by these outer membrane proteins

# Drug_Target_2_SwissProt_ID:
P02929

# Drug_Target_2_SwissProt_Name:
TONB_ECOLI

# Drug_Target_2_Synonyms:
Not Available

# Drug_Target_2_Theoretical_pI:
10.28

# Drug_Target_2_Transmembrane_Regions:
1-32

# Drug_Target_3_Cellular_Location:
Secreted, extracellular space

# Drug_Target_3_Chromosome_Location:
8

# Drug_Target_3_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
Not Available

# Drug_Target_3_GenBank_ID_Gene:
AB018549

# Drug_Target_3_GenBank_ID_Protein:
5051740

# Drug_Target_3_GeneCard_ID:
LY96

# Drug_Target_3_Gene_Name:
LY96

# Drug_Target_3_Gene_Sequence:
>483 bp
ATGTTACCATTTCTGTTTTTTTCCACCCTGTTTTCTTCCATATTTACTGAAGCTCAGAAG
CAGTATTGGGTCTGCAACTCATCCGATGCAAGTATTTCATACACCTACTGTGATAAAATG
CAATACCCAATTTCAATTAATGTTAACCCCTGTATAGAATTGAAAGGATCCAAAGGATTA
TTGCACATTTTCTACATTCCAAGGAGAGATTTAAAGCAATTATATTTCAATCTCTATATA
ACTGTCAACACCATGAATCTTCCAAAGCGCAAAGAAGTTATTTGCCGAGGATCTGATGAC
GATTACTCTTTTTGCAGAGCTCTGAAGGGAGAGACTGTGAATACAACAATATCATTCTCC
TTCAAGGGAATAAAATTTTCTAAGGGAAAATACAAATGTGTTGTTGAAGCTATTTCTGGG
AGCCCAGAAGAAATGCTCTTTTGCTTGGAGTTTGTCATCCTACACCAACCTAATTCAAAT
TAG

# Drug_Target_3_General_Function:
Involved in coreceptor activity

# Drug_Target_3_General_References:
10359581	Shimazu R, Akashi S, Ogata H, Nagai Y, Fukudome K, Miyake K, Kimoto M: MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J Exp Med. 1999 Jun 7;189(11):1777-82.
10891475	Kato K, Morrison AM, Nakano T, Tashiro K, Honjo T: ESOP-1, a secreted protein expressed in the hematopoietic, nervous, and reproductive systems of embryonic and adult mice. Blood. 2000 Jul 1;96(1):362-4.
11160242	Dziarski R, Wang Q, Miyake K, Kirschning CJ, Gupta D: MD-2 enables Toll-like receptor 2 (TLR2)-mediated responses to lipopolysaccharide and enhances TLR2-mediated responses to Gram-positive and Gram-negative bacteria and their cell wall components. J Immunol. 2001 Feb 1;166(3):1938-44.
11435474	Schromm AB, Lien E, Henneke P, Chow JC, Yoshimura A, Heine H, Latz E, Monks BG, Schwartz DA, Miyake K, Golenbock DT: Molecular genetic analysis of an endotoxin nonresponder mutant cell line: a point mutation in a conserved region of MD-2 abolishes endotoxin-induced signaling. J Exp Med. 2001 Jul 2;194(1):79-88.
11593030	Visintin A, Mazzoni A, Spitzer JA, Segal DM: Secreted MD-2 is a large polymeric protein that efficiently confers lipopolysaccharide sensitivity to Toll-like receptor 4. Proc Natl Acad Sci U S A. 2001 Oct 9;98(21):12156-61. Epub 2001 Oct 2.
12642668	Mullen GE, Kennedy MN, Visintin A, Mazzoni A, Leifer CA, Davies DR, Segal DM: The role of disulfide bonds in the assembly and function of MD-2. Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3919-24. Epub 2003 Mar 17.
15489334	Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7.
17569869	Ohto U, Fukase K, Miyake K, Satow Y: Crystal structures of human MD-2 and its complex with antiendotoxic lipid IVa. Science. 2007 Jun 15;316(5831):1632-4.
17803912	Kim HM, Park BS, Kim JI, Kim SE, Lee J, Oh SC, Enkhbayar P, Matsushima N, Lee H, Yoo OJ, Lee JO: Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist Eritoran. Cell. 2007 Sep 7;130(5):906-17.
18810425	Nakajima T, Ohtani H, Satta Y, Uno Y, Akari H, Ishida T, Kimura A: Natural selection in the TLR-related genes in the course of primate evolution. Immunogenetics. 2008 Dec;60(12):727-35. Epub 2008 Sep 23.

# Drug_Target_3_HGNC_ID:
GNC:17156

# Drug_Target_3_HPRD_ID:
Not Available

# Drug_Target_3_ID:
6527

# Drug_Target_3_Locus:
8q21.11

# Drug_Target_3_Molecular_Weight:
18446.2

# Drug_Target_3_Name:
Lymphocyte antigen 96

# Drug_Target_3_Number_of_Residues:
160

# Drug_Target_3_PDB_ID:
Not Available

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF02221	E1_DerP2_DerF2

# Drug_Target_3_Protein_Sequence:
>Lymphocyte antigen 96
MLPFLFFSTLFSSIFTEAQKQYWVCNSSDASISYTYCDKMQYPISINVNPCIELKGSKGL
LHIFYIPRRDLKQLYFNLYITVNTMNLPKRKEVICRGSDDDYSFCRALKGETVNTTISFS
FKGIKFSKGKYKCVVEAISGSPEEMLFCLEFVILHQPNSN

# Drug_Target_3_Reaction:
Not Available

# Drug_Target_3_Signals:
1-18

# Drug_Target_3_Specific_Function:
Cooperates with TLR4 in the innate immune response to bacterial lipopolysaccharide (LPS), and with TLR2 in the response to cell wall components from Gram-positive and Gram-negative bacteria. Enhances TLR4-dependent activation of NF-kappa-B. Cells expressing both MD2 and TLR4, but not TLR4 alone, respond to LPS

# Drug_Target_3_SwissProt_ID:
Q9Y6Y9

# Drug_Target_3_SwissProt_Name:
LY96_HUMAN

# Drug_Target_3_Synonyms:
ESOP-1
Protein MD-2

# Drug_Target_3_Theoretical_pI:
8.46

# Drug_Target_3_Transmembrane_Regions:
None

# Drug_Target_4_Cellular_Location:
Membrane

# Drug_Target_4_Chromosome_Location:
Not Available

# Drug_Target_4_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_4_Essentiality:
Non-Essential

# Drug_Target_4_GenAtlas_ID:
TLR4

# Drug_Target_4_GenBank_ID_Gene:
U93091

# Drug_Target_4_GenBank_ID_Protein:
Not Available

# Drug_Target_4_GeneCard_ID:
Not Available

# Drug_Target_4_Gene_Name:
TLR4

# Drug_Target_4_Gene_Sequence:
>2520 bp
ATGATGTCTGCCTCGCGCCTGGCTGGGACTCTGATCCCAGCCATGGCCTTCCTCTCCTGC
GTGAGACCAGAAAGCTGGGAGCCCTGCGTGGAGGTGGTTCCTAATATTACTTATCAATGC
ATGGAGCTGAATTTCTACAAAATCCCCGACAACCTCCCCTTCTCAACCAAGAACCTGGAC
CTGAGCTTTAATCCCCTGAGGCATTTAGGCAGCTATAGCTTCTTCAGTTTCCCAGAACTG
CAGGTGCTGGATTTATCCAGGTGTGAAATCCAGACAATTGAAGATGGGGCATATCAGAGC
CTAAGCCACCTCTCTACCTTAATATTGACAGGAAACCCCATCCAGAGTTTAGCCCTGGGA
GCCTTTTCTGGACTATCAAGTTTACAGAAGCTGGTGGCTGTGGAGACAAATCTAGCATCT
CTAGAGAACTTCCCCATTGGACATCTCAAAACTTTGAAAGAACTTAATGTGGCTCACAAT
CTTATCCAATCTTTCAAATTACCTGAGTATTTTTCTAATCTGACCAATCTAGAGCACTTG
GACCTTTCCAGCAACAAGATTCAAAGTATTTATTGCACAGACTTGCGGGTTCTACATCAA
ATGCCCCTACTCAATCTCTCTTTAGACCTGTCCCTGAATCCTATGAACTTTATCCAACCA
GGTGCATTTAAAGAAATTAGGCTTCATAAGCTGACTTTAAGAAATAATTTTGATAGTTTA
AATGTAATGAAAACTTGTATTCAAGGTCTGGCTGGTTTAGAAGTCCATCGTTTGGTTCTG
GGAGAATTTAGAAATGAAGGAAACTTGGAAAAGTTTGACAAATCTGCTCTAGAGGGCCTG
TGCAATTTGACCATTGAAGAATTCCGATTAGCATACTTAGACTACTACCTCGATGATATT
ATTGACTTATTTAATTGTTTGACAAATGTTTCTTCATTTTCCCTGGTGAGTGTGACTATT
GAAAGGGTAAAAGACTTTTCTTATAATTTCGGATGGCAACATTTAGAATTAGTTAACTGT
AAATTTGGACAGTTTCCCACATTGAAACTCAAATCTCTCAAAAGGCTTACTTTCACTTCC
AACAAAGGTGGGAATGCTTTTTCAGAAGTTGATCTACCAAGCCTTGAGTTTCTAGATCTC
AGTAGAAATGGCTTGAGTTTCAAAGGTTGCTGTTCTCAAAGTGATTTTGGGACAACCAGC
CTAAAGTATTTAGATCTGAGCTTCAATGGTGTTATTACCATGAGTTCAAACTTCTTGGGC
TTAGAACAACTAGAACATCTGGATTTCCAGCATTCCAATTTGAAACAAATGAGTGAGTTT
TCAGTATTCCTATCACTCAGAAACCTCATTTACCTTGACATTTCTCATACTCACACCAGA
GTTGCTTTCAATGGCATCTTCAATGGCTTGTCCAGTCTCGAAGTCTTGAAAATGGCTGGC
AATTCTTTCCAGGAAAACTTCCTTCCAGATATCTTCACAGAGCTGAGAAACTTGACCTTC
CTGGACCTCTCTCAGTGTCAACTGGAGCAGTTGTCTCCAACAGCATTTAACTCACTCTCC
AGTCTTCAGGTACTAAATATGAGCCACAACAACTTCTTTTCATTGGATACGTTTCCTTAT
AAGTGTCTGAACTCCCTCCAGGTTCTTGATTACAGTCTCAATCACATAATGACTTCCAAA
AAACAGGAACTACAGCATTTTCCAAGTAGTCTAGCTTTCTTAAATCTTACTCAGAATGAC
TTTGCTTGTACTTGTGAACACCAGAGTTTCCTGCAATGGATCAAGGACCAGAGGCAGCTC
TTGGTGGAAGTTGAACGAATGGAATGTGCAACACCTTCAGATAAGCAGGGCATGCCTGTG
CTGAGTTTGAATATCACCTGTCAGATGAATAAGACCATCATTGGTGTGTCGGTCCTCAGT
GTGCTTGTAGTATCTGTTGTAGCAGTTCTGGTCTATAAGTTCTATTTTCACCTGATGCTT
CTTGCTGGCTGCATAAAGTATGGTAGAGGTGAAAACATCTATGATGCCTTTGTTATCTAC
TCAAGCCAGGATGAGGACTGGGTAAGGAATGAGCTAGTAAAGAATTTAGAAGAAGGGGTG
CCTCCATTTCAGCTCTGCCTTCACTACAGAGACTTTATTCCCGGTGTGGCCATTGCTGCC
AACATCATCCATGAAGGTTTCCATAAAAGCCGAAAGGTGATTGTTGTGGTGTCCCAGCAC
TTCATCCAGAGCCGCTGGTGTATCTTTGAATATGAGATTGCTCAGACCTGGCAGTTTCTG
AGCAGTCGTGCTGGTATCATCTTCATTGTCCTGCAGAAGGTGGAGAAGACCCTGCTCAGG
CAGCAGGTGGAGCTGTACCGCCTTCTCAGCAGGAACACTTACCTGGAGTGGGAGGACAGT
GTCCTGGGGCGGCACATCTTCTGGAGACGACTCAGAAAAGCCCTGCTGGATGGTAAATCA
TGGAATCCAGAAGGAACAGTGGGTACAGGATGCAATTGGCAGGAAGCAACATCTATCTGA

# Drug_Target_4_General_Function:
Involved in protein binding

# Drug_Target_4_General_References:
10835634	Arbour NC, Lorenz E, Schutte BC, Zabner J, Kline JN, Jones M, Frees K, Watt JL, Schwartz DA: TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet. 2000 Jun;25(2):187-91.
11081518	Xu Y, Tao X, Shen B, Horng T, Medzhitov R, Manley JL, Tong L: Structural basis for signal transduction by the Toll/interleukin-1 receptor domains. Nature. 2000 Nov 2;408(6808):111-5.
11104518	Smirnova I, Poltorak A, Chan EK, McBride C, Beutler B: Phylogenetic variation and polymorphism at the toll-like receptor 4 locus (TLR4). Genome Biol. 2000;1(1):RESEARCH002. Epub 2000 Apr 27.
11514453	Smirnova I, Hamblin MT, McBride C, Beutler B, Di Rienzo A: Excess of rare amino acid polymorphisms in the Toll-like receptor 4 in humans. Genetics. 2001 Aug;158(4):1657-64.
11706042	da Silva Correia J, Ulevitch RJ: MD-2 and TLR4 N-linked glycosylations are important for a functional lipopolysaccharide receptor. J Biol Chem. 2002 Jan 18;277(3):1845-54. Epub 2001 Nov 12.
9237759	Medzhitov R, Preston-Hurlburt P, Janeway CA Jr: A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature. 1997 Jul 24;388(6640):394-7.
9435236	Rock FL, Hardiman G, Timans JC, Kastelein RA, Bazan JF: A family of human receptors structurally related to Drosophila Toll. Proc Natl Acad Sci U S A. 1998 Jan 20;95(2):588-93.

# Drug_Target_4_HGNC_ID:
HGNC:11850

# Drug_Target_4_HPRD_ID:
Not Available

# Drug_Target_4_ID:
4210

# Drug_Target_4_Locus:
9q32-q33

# Drug_Target_4_Molecular_Weight:
95681

# Drug_Target_4_Name:
Toll-like receptor 4

# Drug_Target_4_Number_of_Residues:
839

# Drug_Target_4_PDB_ID:
Not Available

# Drug_Target_4_Pathway:
Not Available

# Drug_Target_4_Pfam_Domain_Function:
PF00560	LRR_1
PF01463	LRRCT
PF01582	TIR

# Drug_Target_4_Protein_Sequence:
>Toll-like receptor 4
MMSASRLAGTLIPAMAFLSCVRPESWEPCVEVVPNITYQCMELNFYKIPDNLPFSTKNLD
LSFNPLRHLGSYSFFSFPELQVLDLSRCEIQTIEDGAYQSLSHLSTLILTGNPIQSLALG
AFSGLSSLQKLVAVETNLASLENFPIGHLKTLKELNVAHNLIQSFKLPEYFSNLTNLEHL
DLSSNKIQSIYCTDLRVLHQMPLLNLSLDLSLNPMNFIQPGAFKEIRLHKLTLRNNFDSL
NVMKTCIQGLAGLEVHRLVLGEFRNEGNLEKFDKSALEGLCNLTIEEFRLAYLDYYLDDI
IDLFNCLTNVSSFSLVSVTIERVKDFSYNFGWQHLELVNCKFGQFPTLKLKSLKRLTFTS
NKGGNAFSEVDLPSLEFLDLSRNGLSFKGCCSQSDFGTTSLKYLDLSFNGVITMSSNFLG
LEQLEHLDFQHSNLKQMSEFSVFLSLRNLIYLDISHTHTRVAFNGIFNGLSSLEVLKMAG
NSFQENFLPDIFTELRNLTFLDLSQCQLEQLSPTAFNSLSSLQVLNMSHNNFFSLDTFPY
KCLNSLQVLDYSLNHIMTSKKQELQHFPSSLAFLNLTQNDFACTCEHQSFLQWIKDQRQL
LVEVERMECATPSDKQGMPVLSLNITCQMNKTIIGVSVLSVLVVSVVAVLVYKFYFHLML
LAGCIKYGRGENIYDAFVIYSSQDEDWVRNELVKNLEEGVPPFQLCLHYRDFIPGVAIAA
NIIHEGFHKSRKVIVVVSQHFIQSRWCIFEYEIAQTWQFLSSRAGIIFIVLQKVEKTLLR
QQVELYRLLSRNTYLEWEDSVLGRHIFWRRLRKALLDGKSWNPEGTVGTGCNWQEATSI

# Drug_Target_4_Reaction:
Not Available

# Drug_Target_4_Signals:
1-23

# Drug_Target_4_Specific_Function:
Cooperates with LY96 and CD14 to mediate the innate immune response to bacterial lipopolysaccharide (LPS). Acts via MyD88, TIRAP and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response

# Drug_Target_4_SwissProt_ID:
O00206

# Drug_Target_4_SwissProt_Name:
TLR4_HUMAN

# Drug_Target_4_Synonyms:
CD284 antigen
Toll-like receptor 4 precursor
hToll

# Drug_Target_4_Theoretical_pI:
6.26

# Drug_Target_4_Transmembrane_Regions:
632-652

#END_DRUGCARD DB02767
